In Brief: Lilly/Roberts Pharmaceutical
Executive Summary
Lilly/Roberts Pharmaceutical: Companies expand gastrointestinal drugs arrangements as Roberts licenses Lilly's LY315535 for treatment of functional bowel disorders. LY315535 acts as a muscarinic receptor antagonist and as a serotonin (5HT) receptor agonist. Roberts licenses two other compounds for FBD from Lilly, an opioid mu receptor antagonist and a 5-HT4 receptor antagonist ("The Pink Sheet" Nov. 18, T&G-17)...